ArticleNanomaterials (Basel, Switzerland)2020
Graphene Oxide-Linezolid Combination as Potential New Anti-Tuberculosis Treatment.
Article in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Characterization of the Effect of α-Lipoic Acid in Human Macrophages Infected withInternational journal of molecular sciences · 2026Article
- Exploring the Antimicrobial Potential of Vanadium-Based MXenes for Biomedical Applications.MicrobiologyOpen · 2026Article
- Emerging trends of biomedical nanotechnology in nutrition, health monitoring and disease diagnosis.3 Biotech · 2025Review
- Autophagy in mycobacterial infections: molecular mechanisms, host-pathogen interactions, and therapeutic opportunities.Frontiers in cellular and infection microbiology · 2025Review
- Nanomaterial-mediated host directed therapy of tuberculosis by manipulating macrophage autophagy.Journal of nanobiotechnology · 2024Review
- Exploration of the Graphene Quantum Dots-Blue Light Combination: A Promising Treatment against Bacterial Infection.International journal of molecular sciences · 2024Article
- Article
- Unveiling the nanoworld of antimicrobial resistance: integrating nature and nanotechnology.Frontiers in microbiology · 2024Review
- Unraveling the potential of graphene quantum dots againstFrontiers in microbiology · 2024Article
- Advanced drug delivery and therapeutic strategies for tuberculosis treatment.Journal of nanobiotechnology · 2023Review
- Nanotechnology in the COVID-19 era: Carbon-based nanomaterials as a promising solution.Carbon · 2023Review
- Evaluation of the Toxic Activity of the Graphene Oxide in the Ex Vivo Model of Human PBMC Infection withMicroorganisms · 2023Article
- Penicillin and Oxacillin Loaded on PEGylated-Graphene Oxide to Enhance the Activity of the Antibiotics against Methicillin-ResistantPharmaceutics · 2022Article
- Synthesis of covalent bonding MWCNT-oligoethylene linezolid conjugates and their antibacterial activity against bacterial strains.RSC advances · 2021Article
- Graphene nanoplatelet and graphene oxide functionalization of face mask materials inhibits infectivity of trapped SARS-CoV-2.iScience · 2021Article
- Nanoantibiotics: Functions and Properties at the Nanoscale to Combat Antibiotic Resistance.Frontiers in chemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Global pandemic management represents a serious issue for health systems. In some cases, repurposing of existing medications might help find compounds that have the unexpected potential to combat microorganisms. In the same way, changing cell-drug interaction by nanotechnology could represent an innovative strategy to fight infectious diseases. Tuberculosis (TB) remains one of the most alarming worldwide infectious diseases and there is an urgent need for new drugs and treatments, particularly for the emergence and spread of drug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.